Canopy Growth revenue climbs 14% in Q4
Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported a narrower quarterly loss and double-digit full-year revenue growth on Monday, as the Canadian cannabis company cited the acquisition of MTL Cannabis and a strategic recapitalization as key drivers of its turnaround effort. The company posted an adjusted loss per share of $0.29 for its fiscal fourth quarter, missing analyst estimates, though the result represented a 71% improvement from the $1.01 loss in the same period a year earlier.
Canopy Growth Q4 Earnings Call Highlights
Canopy Growth NASDAQ: CGC reported higher fiscal fourth-quarter revenue and said it entered fiscal 2027 with a stronger balance sheet following a year of restructuring, cost cuts and the acquisition of MTL Cannabis.
Canopy Growth Corporation (CGC) Reports Q4 Loss, Lags Revenue Estimates
Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.94 per share a year ago.
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
3 Canadian Marijuana Stocks That Could Help You Make Money
Those who have been investing in marijuana stocks over the years have seen many changes. If you have been investing and trading since just before the pandemic, then you know how exciting the sector can be. With all the changes in the cannabis industry, from regulations to federal legislation, hopes are high for investors. At the start, some were filled with doubt about legal cannabis, let alone investing in marijuana stocks.
Canopy Growth Corporation (CGC) Stock Dips While Market Gains: Key Facts
The latest trading day saw Canopy Growth Corporation (CGC) settling at $1.06, representing a -1.85% change from its previous close.
Top Canadian Marijuana Stocks for Your Watchlist Before June 2026
The Canadian cannabis sector continues showing signs of long-term potential heading into June 2026. Several companies are expanding globally while improving operational efficiency. In addition, many cannabis investors are watching for future developments in the United States' reform. Those possible reforms could create new growth opportunities across the industry. However, volatility remains high in cannabis stocks. Because of this, traders should continue using technical analysis and proper risk management strategies. Strong balance sheets and improving revenue trends are becoming increasingly important for investors. Furthermore, companies with diversified operations may perform better during uncertain market conditions. Three Canadian cannabis companies continue attracting investor attention this month. These companies include TLRY, CGC, and VFF.
Canopy Growth Corporation (CGC) Exceeds Market Returns: Some Facts to Consider
In the latest trading session, Canopy Growth Corporation (CGC) closed at $1.07, marking a +1.9% move from the previous day.
Should You Buy CGC Stock After Marijuana Reclassification?
Canopy Growth gains attention as marijuana reclassification boosts cannabis sentiment, but margin pressure and execution risks persist.
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Canopy Growth Corporation (CGC) Dipped More Than Broader Market Today
Canopy Growth Corporation (CGC) closed the most recent trading day at $0.98, moving 5.55% from the previous trading session.
Canadian Marijuana Stocks Showing Strong Momentum in May
Canadian cannabis stocks remain active in May 2026. Investors continue watching the sector for growth opportunities and reform catalysts. In addition, many traders expect future federal progress in the United States. That possibility has increased interest across the entire cannabis market. Recent headlines surrounding possible cannabis rescheduling also boosted momentum in leading names.
